AMF Tjanstepension AB Acquires 17,999 Shares of Humana Inc. $HUM

AMF Tjanstepension AB raised its holdings in shares of Humana Inc. (NYSE:HUM) by 24.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 91,901 shares of the insurance provider’s stock after purchasing an additional 17,999 shares during the quarter. AMF Tjanstepension AB owned 0.08% of Humana worth $23,910,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Humana by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 14,199,096 shares of the insurance provider’s stock valued at $3,471,395,000 after buying an additional 226,224 shares during the period. Dodge & Cox raised its stake in shares of Humana by 5.6% during the second quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock valued at $2,775,562,000 after acquiring an additional 597,705 shares in the last quarter. State Street Corp boosted its holdings in shares of Humana by 1.1% in the second quarter. State Street Corp now owns 5,377,390 shares of the insurance provider’s stock valued at $1,319,334,000 after purchasing an additional 58,094 shares during the period. Pzena Investment Management LLC grew its stake in Humana by 6.5% in the second quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider’s stock worth $996,664,000 after purchasing an additional 247,744 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in Humana by 273.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,488,261 shares of the insurance provider’s stock worth $907,541,000 after purchasing an additional 2,553,509 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Down 0.2%

NYSE:HUM opened at $265.68 on Friday. The company’s 50-day simple moving average is $258.26 and its 200-day simple moving average is $264.66. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 2.02. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The stock has a market capitalization of $31.95 billion, a P/E ratio of 24.90, a P/E/G ratio of 2.19 and a beta of 0.45.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.29. The company had revenue of $32.65 billion during the quarter, compared to analysts’ expectations of $31.99 billion. Humana had a net margin of 1.02% and a return on equity of 12.86%. Humana’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.16 earnings per share. On average, equities analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.3%. Humana’s dividend payout ratio (DPR) is presently 33.18%.

Analysts Set New Price Targets

Several brokerages have weighed in on HUM. Bank of America upped their target price on Humana from $280.00 to $300.00 and gave the stock a “neutral” rating in a report on Friday, October 10th. Truist Financial dropped their target price on shares of Humana from $300.00 to $285.00 and set a “hold” rating on the stock in a report on Monday, November 10th. Zacks Research lowered shares of Humana from a “hold” rating to a “strong sell” rating in a report on Thursday, January 1st. Jefferies Financial Group raised shares of Humana from a “hold” rating to a “buy” rating and upped their price target for the stock from $253.00 to $313.00 in a research report on Friday, December 5th. Finally, Robert W. Baird cut their price objective on shares of Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a report on Thursday, December 11th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $293.37.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.